Skip to main content
Livermore
Livermore
ZHEN

Foresite Capital Opportunity Management V, LLC

SEC CIK
0001792207
Latest filing
Nov 14, 2022

The latest 13F from Foresite Capital Opportunity Management V, LLC covers Q3 2022 (filed Nov 14, 2022): 9 long positions worth $33.3M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Pardes Biosciences, Inc. (PRDS) at 29.0%. Livermore has 4 filings on Form 13F from this institution, going back to Q4 2021.

What changed in Q3 2022

Share counts compared with Q2 2022: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
0
Added
0
Reduced
0
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. PRDSPardes Biosciences, Inc.
    29.0%$9.67MHistory
  2. THRXTheseus Pharmaceuticals, Inc.
    16.7%$5.56MHistory
  3. IRONDisc Medicine, Inc.
    12.0%$3.99MHistory
  4. CMPXCompass Therapeutics, Inc.
    10.6%$3.54MHistory
  5. KNTEKinnate Biopharma Inc.
    10.5%$3.48MHistory

Share of portfolio

Top 5 holdings and the other 4 positions, by share of portfolio value

  1. PRDS29.0%
  2. THRX16.7%
  3. IRON12.0%
  4. CMPX10.6%
  5. KNTE10.5%
  6. Other 4 positions21.2%

Biggest buys

New and added positions, by estimated amount bought

None this quarter.

Largest weight increases

New and added positions, by percentage points of the portfolio gained

None this quarter.

Biggest sells

Reduced and sold-out positions, by estimated amount sold

None this quarter.

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

None this quarter.

Metrics

13F metrics for Q3 2022, computed only from the numbers in the filings. Definitions below.

Portfolio value
$33.3M
−$6.37M (−16.1%) vs. prior quarter
Positions
9
0 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
0.0%
Q3 2022, one quarter
Average holding period
3.9 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2021), so positions held before then are understated.

13F filings by quarter

4 quarters, going back to Q4 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $149.2M (Q4 2021)

Q4 2021: $149.2MQ1 2022: $71.4MQ2 2022: $39.7MQ3 2022: $33.3M
Q4 2021Q3 2022
13F filings of Foresite Capital Opportunity Management V, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q3 2022Nov 14, 20229$33.3MPRDSTHRXIRONvs. Q2 2022SEC
Q2 2022Aug 12, 20229$39.7MPRDSTHRXCMPXvs. Q1 2022SEC
Q1 2022May 13, 202210$71.4MPRDSQSITHRXvs. Q4 2021SEC
Q4 2021Feb 11, 20229$149.2MPRDSHLTHQSI–SEC

13D and 13G filings

Companies where Foresite Capital Opportunity Management V, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Foresite Capital Opportunity Management V, LLC does not currently report owning 5% or more of any company.

Latest filings

12 filings on file made by Foresite Capital Opportunity Management V, LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Foresite Capital Opportunity Management V, LLC
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
LTGOLatigo Biotherapeutics, Inc.Aug 17, 20267:06 PM ETForesite Capital Fund VI LPand 6 others13D14.50%9.18M sharesNewAug 10, 2026SEC
ALMSAlumis Inc.Aug 17, 20266:09 AM ETForesite Capital Fund VI LPand 6 others13D14.50%9.18M sharesNewAug 10, 2026SEC
LYELLyell Immunopharma, Inc.Aug 14, 20264:03 PM ETForesite Capital Fund IV, L.P.and 6 others13G/A2.70%653.3K shares−4.90 ppfrom 7.60%Below 5%Jun 30, 2026SEC
CGONCG Oncology, Inc.Aug 14, 20264:01 PM ETForesite Capital Fund V, L.P.and 6 others13G/A4.90%4.31M shares–Below 5%Jun 30, 2026SEC
ALMSAlumis Inc.Apr 3, 20263:51 PM ETForesite Capital Fund VI LPand 11 others13D/A12.70%15.7M shares−1.40 ppfrom 14.10%Apr 1, 2026SEC
EIKNEikon Therapeutics, Inc.Feb 11, 20264:08 PM ETForesite Capital Fund IV, L.P.and 8 others13G7.70%4.15M sharesNewFeb 4, 2026SEC
ALMSAlumis Inc.Jan 12, 20269:59 PM ETForesite Capital Fund VI LPand 11 others13D/A14.10%16.2M shares−1.80 ppfrom 15.90%Jan 8, 2026SEC
LYELLyell Immunopharma, Inc.Nov 14, 20254:05 PM ETForesite Capital Fund IV, L.P.and 6 others13G/A7.60%1.45M shares−1.60 ppfrom 9.20%Sep 30, 2025SEC
ALMSAlumis Inc.Jun 10, 20254:37 PM ETForesite Capital Fund VI LPand 11 others13D/A15.90%15.2M shares−16.30 ppfrom 32.20%May 21, 2025SEC
LYELLyell Immunopharma, Inc.May 15, 20254:04 PM ETForesite Capital Fund IV, L.P.and 6 others13G/A9.20%27.2M shares+2.50 ppfrom 6.70%Mar 31, 2025SEC
ALMSAlumis Inc.May 7, 20253:33 PM ETForesite Capital Fund VI LPand 11 others13D/A32.20%15.2M shares–Aug 13, 2024SEC
LYELLyell Immunopharma, Inc.Feb 14, 20252:20 PM ETForesite Capital Fund IV, L.P.and 6 others13G/A6.70%19.5M shares–Dec 31, 2024SEC